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Abstract
Background: Tumor angiogenesis is important in the progression of malignancies, and heparanase plays an
important role in sustaining the pathology of clear cell renal cell cancer (ccRCC). The study was carried out to
investigate the correlations between microvessel density (MVD) and heparanase expression containing prognostic
significances in the patients with ccRCC.
Methods: Specimens from 128 patients with ccRCC were investigated by immunohistochemistry for MVD. RT-PCR
and immunohistochemistry were used to detect heparanase expression. Correlations between MVD, heparanase
expression, and various clinico-pathological factors were studied. The prognostic significances of MVD and
heparanase expression were also analysed.
Results: We discovered a statistically significant prevalence of higher MVD in ccRCC compared with adjacent
normal renal tissues. MVD was positively correlated with TNM stage and distant metastasis in ccRCC patients, and
was also correlated with the expression level of heparanase.
Heparanase is over-expressed and correlated with TNM stage, histologic grade, distant metastasis and lymphatic
metastasis in ccRCC. High MVD and heparanase over-expression inversely correlate with the survival of ccRCC
patients.
Conclusions: Heparanase contributes to angiogenesis of ccRCC and over-expression of heparanase is an
independent predictors of prognosis for ccRCC. MVD is correlated with tumor development and metastasis in
ccRCC.
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Background
Renal cell carcinoma (RCC) is the most common malig-
nant tumor of adult kidney [1]. Approximately 30% of
the patients will develop to metastatic disease after cura-
tive surgery [2]. Clear cell renal cell carcinoma(ccRCC)
is the most pathological types of RCC which has various
clinical-pathological characteristics and prognostic fac-
t o r s .A n g i o g e n e s i si so n eo ft h em a j o rf a c t o r si nt h e
progression of malignancies, and tissue angiogenesis can
be quantified by counting microvasculars in a certain
area by immunohistochemical staining (microvessel den-
s i t y ,M V D )[ 3 ] .S of a rM V Dh a sb e e nc o n s i d e r e da sa
potential prognostic marker in some tumors [4,5].
Heparanase(HPA) is an endo-b-D-glucuronidase that
has the activity of cleaving heparan sulfate (HS) side
chains of heparan sulfate proteoglycans (HSPGs) [6].
HSPGs are not only the major proteoglycans of the extra-
cellular matrix (ECM) and basement membrane (BM)
which play a key role in preventing tumor cells invasion
and metastasis, but also expressed on cell surfaces [7]. It is
well known that heparanase activity is concerned with
angiogenesis, inflammation, and cancer metastasis [8].
Heparanase over-expression inversely correlates with sur-
vival of patients with gastric [9], pancreatic [10], cervical
[11], colorectal [12], bladder [13] and prostate [14] cancer.
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nase and MVD has not been so far done in previous stu-
dies. Our study examined MVD and heparanase
expression in 128 patients with ccRCC and analyzed the
correlations between the clinical-pathological parameters
including MVD and heparanase expression. Moreover,
we analyzed the prognostic significances of MVD and
heparanase expression for ccRCC.
Methods
Patients
The tumour specimens and corresponding normal renal
tissues were obtained from 128 patients with ccRCC
between 2002 and 2008. All the ccRCCs were staged
according to the 1997 TNM staging system [15]. Nuclear
grade was on the basis of the Fuhrman criteria [16]. Clini-
cal data of all the patients were collected from hospitaliza-
tion and subsequent records. All the patients were
informed of the study and consented to using their renal
tissues for the investigation. Our study was also approved
by the local ethics committee. All the patients were under-
went radical nephrectomy, and none of them received che-
motherapy or radiation therapy before surgery. The
specimens were stored in liquid nitrogen for RT-PCR, and
paraffin-embedded sections were prepared for immuno-
histochemistry analysis. We were keeping follow-up of 70
patients, 28 of them were alive at the end of the follow-up.
Detailed information is listed in Table 1.
Immunohistochemistry
Five-micron paraffin sections were prepared for the
experiment. Staining of the sections for heparanase was
performed as previously described [17]. SP immunohisto-
chemistry method and DBA staining were performed.
Block nonspecific binding was performed with 5% bovine
serum albumin(BSA) for 60 minutes at room temperature,
Table 1 MVD and Expression of HPA According To Clinical-pathological Parameters in ccRCC Tissues
Variables n % HPA P MVD P
-+
Total 128 100 32 96 101.64 ± 23.00
Gender
Male 82 64.1 21 61 0.832 101.39 ± 24.54 0.133
Female 46 35.9 11 35 102.07 ± 20.04
Age, Years (Median 55)
≤ 55 61 47.7 15 46 0.919 102.02 ± 20.49 0.069
> 55 67 52.3 17 50 101.27 ± 25.14
Tumor size
≤ 5 cm 83 64.8 20 63 0.748 101.93 ± 24.53 0.058
> 5 cm 45 35.2 12 33 101.11 ± 19.92
Tumor stage
T1 50 39.1 20 30
T2 41 32 8 33
T3 27 21.1 3 24
T4 10 7.8 1 9
Lymphatic metastasis
N0 108 84.4 31 77 0.025 101.81 ± 23.84 0.056
N1-3 20 15.6 1 19 100.72 ± 17.91
Distant metastasis
M0 114 89.1 32 82 0.022 99.96 ± 23.66 < 0.0001
M1 14 10.9 0 14 113.14 ± 12.88
TNM stage
I-II 76 59.4 27 49 0.001 95.96 ± 21.39 < 0.0001
III-IV 52 40.6 5 47 108.94 ± 22.94
Histologic grade
G1-G2 94 73.4 27 67 0.106 101.49 ± 24.02 0.238
G3-G4 34 26.6 5 29 102.04 ± 20.00
Venous invasion
Negative 106 82.8 26 80 0.787 101.79 ± 23.99 0.109
Positive 22 17.2 6 16 100.91 ± 17.61
-: negative expression +: positive expression
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Page 2 of 8without washing, and the slides were incubated with anti-
heparanase antibody (sc-25825, 1:100 dilution) and anti-
CD34 antibody (sc-19621, 1:100 dilution) at 4°C overnight.
As a negative control, the primary antibody was replaced
with phosphatebuffered saline (PBS). After washing with
PBS, the slides were incubated with horseradish peroxi-
dase-conjugated goat anti-rabbit IgG according to the
manufacturer’s instructions at 37°C for 45 min. Color was
developed with DAB Horseradish Peroxidase Color Devel-
opment Kit (P0202, Beyotime). The slides were evaluated
by two independent pathologists who were blind to the
status of the patients according to the intensity of cancer
cells that were stained (-: negative, +: weak, ++: strong) as
described [18].
Quantification of Microvasculature Density
The primary antibody against CD34 was used to evaluate
microvessel density (MVD), which was performed accord-
ing to the methods previously described [19]. Endothelial
cell clusters and endothelial cells which were stained
brownish-yellow could be considered as a single microves-
sel. Undefined endothelial cell fragments and the visible
vascular lumen were not counted as microvessels. Branch-
ing structures were considered as single vessel if there was
not a break in continuity of the structure. Initially, the
entire section was scanned for high-MVD areas by low
microscopic magnification (40× and 100×) to identify the
hot spots (representing the highest vascular density), and
then brown-stained endothelial clusters were counted
under light microscope observation 200× magnification.
Results were shown as mean microvessel counts of the
three hot spots under 200× magnification [20]. High MVD
group and low MVD group were classified by the the
median MVD counts of ccRCC patients. Figure 1A-1
showed a representative field of high MVD in ccRCC. For
comparison, Figure 1A-2 depicted a representative field of
ccRCC with low MVD.
RNA isolation and semi-quantitative reverse transcriptase
polymerase chain reaction (RT-PCR)
Total RNA was extracted from RCC tissues and adjacent
normal renal tissues using TRIzol (Invitrogen) according
to the manufacturer’s instructions, and then quantified by
spectrophotometry. The polymerase chain reaction (PCR)
primers designed by Premier Primer 5.0 software were as
following: heparanase-5’-TTCGATCCCAAGAAGGAAT-
CAAC-3’ (forward) and 5’-GTAGTGATGCCATGTAAC
TGAATC-3’(reverse), and b-actin-5’- GTGGGG CGC
CCCAGGCACCA-3’(forward) and 5’-CTCCTTAATGT-
CACGCACGATTTC-3’(reverse). PCR products were
separated by electrophoresis through a 1.5% agarose gel,
stained by ethidium bromide, and visualized in ultraviolet
light. The intensity of the bands was quantified with Scion
Image software (Scion, Frederick, MD).
Statistical Analysis
MVD differentials were compared using t-test and uni-
variate analysis of variance. Associations between hepara-
nase expression and clinical-pathological parameters
were analyzed using Chi Square test. Univariate associa-
tion of survival was evaluated using Kaplan Meier curves,
and tested by Log-Rank test. Multivariate analyses were
performed according to Cox proportional hazards regres-
sion mode. (SPSS version 16.0 for Mac; SPSS, Inc., Chi-
cago, IL, USA). P < 0.05 was considered to be statistically
significant.
Results
The correlation of MVD in ccRCC with the clinical-
pathological parameters
The mean MVD counts were 101.64 ± 23.00 in ccRCC tis-
sues, 32.52 ± 7.85 in corresponding normal renal tissues,
with significant difference (P < 0.0001); The relationship
between MVD counts and various clinical and histopatho-
logic parameters was analyzed. The mean MVD counts
were 108.94 ± 22.94 in advanced stage group (stage III-IV),
95.96 ± 21.39 in early stage group (stage I-II), with signifi-
cant difference (P < 0.0001); 113.14 ± 12.88 in M1 group
(with distant metastasis), 99.96 ± 23.66 in M0 group (with-
out distant metastasis), with significant difference (P <
0.0001); No significant association was demonstrated
between MVD counts and patients’ age (≤55 years:102.02 ±
20.49, >55 years: 101.27 ± 25.14, P =0 . 0 6 9 ) ,g e n d e r( m :
101.39 ± 24.54, f: 102.07 ± 20.04, P = 0.113), tumour sizes
(≤5 cm:101.93 ± 24.53, >5 cm: 101.11 ± 19.92, P = 0.058),
histologic grade (G1-G2: 101.49 ± 24.02, G3-G4:1 0 2 . 0 4±
20.00, P = 0.238), lymphatic metastasis (N0: 101.81 ± 23.84,
N1-2: 100.72 ± 17.91, P = 0.056) and venous invasion (V0:
101.79 ± 23.99, V1: 100.91 ± 17.61, P =0 . 1 0 9 )( T a b l e1 ) .
Heparanase is over-expressed and correlated with
progression and invasion in ccRCC
Expression of heparanase was observed in 96 tumour
samples (75%) (Figure 1B and 1C), conversely in 25 adja-
cent normal tissues (19.5%) (P < 0.0001). Heparanase
expression was correlated with TNM staging (P =0 . 0 0 1 ) ,
distant metastasis (P = 0.022) and lymphatic metastasis
(P = 0.025) (Table 1).
Correlations between MVD and heparanase expression
The mean MVD counts in the group of heparanase-nega-
tive expression, weak heparanase expression and strong
heparanase expression were 97.37 ± 21.13, 101.86 ± 22.53
and 103.97 ± 24.10 (P < 0.0001), respectively.
MVD, heparanase expression and postoperative survival
of the patients
The overall survival (OS) rate of patients with high-
MVD was significantly lower than that with low-MVD
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Page 3 of 8(Log-Rank Test, P = 0.022, Figure 2A). The OS rate of
patients with heparanase- positive was significantly
lower than that with heparanase-negative (Log-Rank
Test, P < 0.0001, Figure 2B). In addition, the multivari-
ate analysis indicated that heparanase-positive expres-
sion (P =0 . 0 0 6 )a n dd i s t a n tm e t a s t a s i s( P < 0.0001)
were independent prognostic factors for ccRCC patients
(Table 2).
Rates and P values in disease-specific survival accord-
ing to the status of MVD and heparanase expression
w e r ea c t u a l l ye q u a lt ot h o s ei no v e r a l ls u r v i v a lo ft h e
patients.
Figure 1 MVD and heparanase expression in ccRCC. (A) MVD in ccRCC tissues of immunostaining (×400). A-1: high MVD, A-2: low MVD (B)
Heparanase protein expression in ccRCC tissues of immunostaining (×400). B-1: strong expression, B-2: weak expression. (C) Heparanase mRNA
expression in ccRCC tissues (T) and corresponding adjacent normal renal tissues (N).
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As shown in previous studies, heparanase plays an
important role in sustaining the pathology of various
malignancies [14,17,21-24]. Invasion and metastasis of
tumor cells depend on the ability of the cells invading
tissue barriers which are composed of BM and ECM.
HS and HSPGs, as crucial structural components, are
contained in BM and ECM, and are substrates of
Figure 2 Survival Curves of the Patients with ccRCC. (A) on the basis of MVD counts in tumor tissues, 1: low MVD group, 2: high MVD group
(B) on the basis of HPA expression in tumor tissues, 1: negative expression group, 2: positive expression group.
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[25]. Consequently, tumor cells are facilitated penetrat-
ing the BM and ECM barriers. This enzymatic activity
of heparanase contributes to the development of ccRCC.
Thus, heparanase may play biological roles in multiple
ways other than its enzymatic activity, such as mediation
of cell adhesion [26], activation of CD44 variant exon-3
[27], promoting VEGF expression via Src pathway [28],
enhancing Akt signaling pathway and stimulating PI3K-
and p38-dependent endothelial cell migration and inva-
sion [29], modulation of endothelial cell permeability
and integrity via syndecan family members [30,31], pro-
motion of basic fibroblast growth factor releasing and
inhibition of activated T lymphocytes [32], and so on.
Degradation of the subendothelial BM, migration and
proliferation of the endothelial cells to form vascular
sprouts are crucial early events during angiogenesis [33].
The activities of heparanase and some growth factors
binding HS, such as aFGF (acid fibroblast growth factor),
bFGF (basic fibroblast growth factor), VEGF (vascular
endothelial growth factor) are directly involved in above
progresses [28]. Furthermore, cell surface HS can interact
with HS binding growth factors and facilitate the signal
transduction [34]. Heparanase promotes migration and
proliferation of the endothelial cells by above mechanism
[25]. Accordingly, we evaluated the angiogenesis of ccRCC
by detecting commonly used pan-endothelial marker
(CD34) as previous studies [5,35].
Our study found the prevalence of elevated angiogenesis
and heparanase over-expression in ccRCC, at the same
time, we firstly described the close correlations between
angiogenesis and heparanase expression in ccRCC. Tumor
angiogenesis was closely related to the development and
metastasis of ccRCC, and heparanase over-expression was
associated with invasion and prognosis that was consistent
with previous description [36]. Above results indicated
that antiangiogenesis by inhibiting heparanase maybe
more effective treatment for ccRCC.
The study showed poor survival of patients with high
MVD and heparanase over-expression. Tumor size,
tumor stage, nuclear grade, and metastasis status have
been reported to be of prognostic significance for RCC
[37,38]. Our study showed that high MVD had prognos-
tic significance for ccRCC, which was not consistent
with previous description [39].
In view of the above, heparanase may serve as a thera-
peutic target for ccRCC. In fact, PI-88, a representative
heparanase inhibitor, has already been tested in clinical
trial [40-42]. The application of heparanase inhibitors
may be a promising therapeutic tool for ccRCC in
particular.
Taken together, our findings demonstrate the tumor
angiogenesis and the role of heparanase in ccRCC on the
basis of clinical and pathological parameters, thus contri-
buting to the basic understanding of the most common
malignant tumour of adult kidney. In addition, the role of
heparanase in tumor angiogenesis, the prognostic signifi-
cance of heparanase over-expression for ccRCC are
described.
Conclusions
Elevated angiogenesis is observed in ccRCC but almost
absent in normal renal tissues. Elevated angiogenesis con-
tributes to development and invasion of ccRCC. Hepara-
nase over-expression is prevalent in ccRCC, which
promotes tumor angiogenesis and indicates worse prog-
nosis. Moreover, heparanase over-expression is an inde-
pendent predictor of prognosis for ccRCC. Therefore,
heparanase may serve as a potential therapeutic target for
ccRCC.
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